Dr. Johnson has served as interim CEO since November 2014, following the seven-year tenure of CEO Donald Trump, MD. She was also promoted in November to be cancer center director. In this role, she is the principal investigator of the hospital’s $19 million cancer center support grant from the National Cancer Institute.
Dr. Johnson previously served as deputy director, chair of the department of pharmacology and therapeutics, the Wallace Family Chair for translational research and a professor of oncology at RCPI.
Before coming to RCPI in 2002, Dr. Johnson served as deputy director of basic research at the University of Pittsburgh Cancer Institute. She holds a doctorate in immunology from Ohio State University.
She is a member of the National Institutes of Health Reviewers and has served multiple terms on committees for the National Cancer Institute.
More CEO profiles:
CEO to know: Dr. David Herman of Essentia Health
CEO to know: Bill Leaver of UnityPoint Health
CEO to know: Dr. Gianrico Farrugia of Mayo Clinic’s Florida campus
At Becker's 4th Annual CEO + CFO Roundtable, taking place November 2–5 in Chicago, more than 1,500 hospital and health system executives tackle decisions that determine whether organizations thrive or merely survive: protecting margins under cost pressure, choosing where to grow, renegotiating payer relationships, stabilizing the workforce and proving real ROI on technology. This is where leaders work through them together, face-to-face. Apply for complimentary registration now.